Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg
 (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in
 subjects with healed erosive gastroesophageal reflux disease (eGERD).
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects
 who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups,
 rabeprazole extended release 50 mg (once daily) or ranitidine 150 mg (twice daily).

 Please note that this study is not a duplicate of E3810-G000-305; this is a separate study
 being conducted along with -305.
KEY INCLUSION CRITERIA:

 1. Prior completion of Study E3810-G000-302 or -303. Subjects will need to have healed
 erosive esophagitis (absence of esophageal mucosal breaks or erosions) confirmed by EGD and
 sustained resolution of heartburn at Visit 4 or 5 of Study E3810-G000-302 or -303.

 KEY EXCLUSION CRITERIA:

 1. Esophageal motility disorders (achalasia, scleroderma, or esophageal spasm).

 2. Barrett's esophagus or esophageal stricture.

 3. Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine
 receptor antagonists (H2RA), antacids, sucralfate, misoprostol, prokinetics or drugs
 with significant anticholinergic effects throughout the study.

 4. Subjects who require chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs),
 oral steroids (>= 20 mg/day prednisone or equivalent), or aspirin (->; 325 mg/day).

 5. Significant hepatic, renal, respiratory, endocrine, hematologic, neurologic,
 psychiatric, or cardiovascular system abnormalities that would be likely to interfere
 with the conduct of the study, the interpretation of study results, or the health of
 the subject during the study.

 6. Any condition that would make the subject, in the opinion of the Investigator or
 Sponsor, unsuitable for the study.